Trials / Withdrawn
WithdrawnNCT04044742
A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee
A Phase 3 Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sorrento Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 35 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the efficacy and safety of intra-articular injection of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.
Detailed description
This study is to evaluate the analgesic efficacy and safety of resiniferatoxin administered intra-articularly to subjects with moderate to severe knee pain due to osteoarthritis (OA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resiniferatoxin | Receiving Resiniferatoxin injection |
| DRUG | Placebo | Receiving Placebo injection |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2023-03-01
- Completion
- 2023-03-01
- First posted
- 2019-08-05
- Last updated
- 2021-11-09
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04044742. Inclusion in this directory is not an endorsement.